|
|
| Use these links to jump to a section further down the page. |
Investment Objective
The fund seeks capital appreciation.
top of page ^
Fund Description
The fund seeks to capitalize on the strength and diversity of companies within the health care sector. The fund seeks companies that offer strong long-term growth prospects, regardless of their size. Holdings encompass an array of industries, including pharmaceuticals, health-care services, and biotechnology.
top of page ^
| Fund Returns |
| As of Quarter End June 30, 2007 | All returns in percentages |
| Class |
Last
Quarter |
Year
to Date |
1
Year |
3
Year |
5
Year |
10 Years |
Life of
Fund |
| A |
NAV |
3.18% |
4.40% |
12.21% |
9.02% |
7.72% |
6.24% |
13.00% |
| |
POP |
-2.24% |
-1.07% |
6.33% |
7.07% |
6.56% |
5.67% |
12.75% |
| |
Inception date: May 28, 1982 |
| B |
NAV |
2.99% |
4.01% |
11.35% |
8.20% |
6.92% |
5.45% |
12.05% |
| |
CDSC |
-2.01% |
-0.99% |
6.36% |
7.36% |
6.61% |
5.45% |
12.05% |
| |
Inception date: March 1, 1993 |
| C |
NAV |
3.01% |
4.02% |
11.37% |
8.20% |
6.92% |
5.46% |
12.15% |
| |
POP |
2.01% |
3.02% |
10.37% |
8.20% |
6.92% |
5.46% |
12.15% |
| |
Inception date: July 26, 1999 |
| M |
NAV |
3.07% |
4.14% |
11.66% |
8.47% |
7.19% |
5.72% |
12.34% |
| |
POP |
-0.28% |
0.76% |
8.03% |
7.29% |
6.48% |
5.37% |
12.20% |
| |
Inception date: July 3, 1995 |
| S & P 500 |
| |
NAV |
6.28% |
6.96% |
20.59% |
11.68% |
10.71% |
7.13% |
|
| S&P 500 Healthcare Equal Weighted Index |
| |
NAV |
6.64% |
11.39% |
23.45% |
13.14% |
13.83% |
12.94% |
|
Fund Returns |
| As of Month End July 31, 2007 | All returns in percentages |
| Class |
Last
Quarter |
Year
to Date |
1
Year |
3
Year |
5
Year |
10 Years |
Life of
Fund |
| A |
NAV |
--- |
--- |
3.28% |
9.28% |
7.69% |
5.41% |
12.76% |
| |
POP |
--- |
-5.25% |
-2.15% |
7.34% |
6.54% |
4.84% |
12.52% |
| |
Inception date: May 28, 1982 |
| B |
NAV |
--- |
-0.45% |
2.50% |
8.46% |
6.89% |
4.62% |
11.82% |
| |
CDSC |
--- |
-5.42% |
-2.10% |
7.62% |
6.58% |
4.62% |
11.82% |
| |
Inception date: March 1, 1993 |
| C |
NAV |
--- |
-0.44% |
2.51% |
8.47% |
6.89% |
4.63% |
11.92% |
| |
POP |
--- |
-1.43% |
1.59% |
8.47% |
6.89% |
4.63% |
11.92% |
| |
Inception date: July 26, 1999 |
| M |
NAV |
--- |
-0.29% |
2.78% |
8.75% |
7.16% |
4.88% |
12.10% |
| |
POP |
--- |
-3.53% |
-0.57% |
7.55% |
6.46% |
4.54% |
11.96% |
| |
Inception date: July 3, 1995 |
 |
Data is historical. Past performance is no guarantee of future results. More recent returns may be worth more or less than those shown. Investment return and principal value will fluctuate, and you may have a gain or loss when you sell your shares. For the most recent month-end performance, visit www.putnaminvestments.com.
Performance assumes reinvestment of distributions and does not account for taxes. Returns at public offering price (POP) for class A and class M shares reflect the current maximum initial sales charges of 5.25% and 3.25% for equity funds, and 3.75% and 3.25% for income funds (3.25% and 2.00% for Putnam Limited Duration Government Income Fund and Putnam Floating Rate Income Fund), respectively. POP performance of income funds' class A shares (other than Putnam Limited Duration Government Income Fund and Putnam Floating Rate Income Fund) and equity funds' class M shares reflects a reduction in maximum sales charge that took effect April 1, 2005. Class B share returns reflect the applicable contingent deferred sales charge (CDSC), which is 5% in the first year, declines to 1% in the sixth year, and is eliminated thereafter (except for Putnam Limited Duration Government Income Fund and Putnam Floating Rate Income Fund, which is 3% in the first year, declines to 1% in the fourth year, and is eliminated thereafter). Class C shares reflect a 1% CDSC the first year that is eliminated thereafter. Performance for class B, C, M, R, T, and Y shares prior to their inception is derived from the historical performance of class A shares, adjusted for the applicable sales charge (or CDSC) and, except for class Y shares, the higher operating expenses for such shares (with the exception of Putnam Tax-Free High Yield Fund and Putnam AMT-Free Insured Municipal Fund, which are based on the historical performance of class B shares). Class A, M, and T shares of Putnam money market funds have no initial sales charge. For a portion of the period some funds may have limited expenses or been sold on a limited basis with limited assets and expenses, without which returns would be lower. A short-term trading fee of up to 1% may apply.
The S&P 500 Index is an unmanaged index of common stock performance. Securities in the fund do not match those in the indexes and performance of the fund will differ. It is not possible to invest directly in an index.
The fund concentrates its investments in one region or in one sector and involves more risk than a fund that invests more broadly.
Growth investing targets companies with above-average earnings that may be subject to price volatility if earnings expectations are not met.
You can lose money by investing in a fund. Any given fund may not achieve its goal, and is not intended as a complete investment program. All funds have risk. The value and/or returns of a portfolio will fluctuate with market conditions. You may have more or less than the original amount invested when you redeem your shares.
top of page ^
Expense Ratio
| Class |
Fund's total expense ratio |
What you pay |
top of page ^
| Class |
1 Year |
3 Years |
5 Years |
10 Years |
| Lipper Category: Health/Biotechnology |
| A |
92% (160/174) |
43% (65/152) |
85% (115/135) |
87% (31/35) |
| B |
96% (168/174) |
54% (82/152) |
89% (121/135) |
92% (33/35) |
| C |
96% (167/174) |
53% (81/152) |
89% (121/135) |
--- |
| M |
94% (163/174) |
50% (76/152) |
89% (120/135) |
89% (32/35) |
Lipper Analytical Services, Inc. is an industry research firm whose rankings are based on total return performance and do not reflect the effect of sales charges. Each fund is ranked within a universe of funds similar in investment objective. Past performance is no guarantee of future results.
top of page ^
| Top 10 Holdings | Holdings will vary over time |
| As of July 31, 2007 | Holdings represent 46.51% of portfolio |
| Rank |
Fund |
Percentage of Portfolio |
| 1. |
Roche Hldg-Genus Sedol 7110388 |
6.22% |
| 7. |
Novartis-Reg Shs Sedol 7103065 |
4.20% |
| 10. |
Biogen Idec Inc |
3.03% |
top of page ^
| Rank |
Sector |
Percentage of Portfolio |
| 1. |
Pharmaceuticals |
41.47% |
| 2. |
Medical Technology |
22.48% |
| 4. |
Healthcare Services |
15.30% |
top of page ^
Country Allocation
Not available
top of page ^
top of page ^
| Class |
Record/Ex
Dividend Date |
Payable
Date |
Income |
ST Cap Gain |
LT Cap Gain |
| A |
12/04/2006 |
12/11/2006 |
$0.235000 |
$0.879000 |
$4.990000 |
| B |
12/04/2006 |
12/11/2006 |
|
$0.879000 |
$4.990000 |
| C |
12/04/2006 |
12/11/2006 |
|
$0.879000 |
$4.990000 |
| M |
12/04/2006 |
12/11/2006 |
|
$0.879000 |
$4.990000 |
top of page ^
| Fiscal Year End | August |
| Fund Status | Open to new investors |
| Dividend Frequency | Annually |
| Number of Issues | 58 |
| Turnover (as of fiscal year end) | 16.99% |
| Class |
Inception |
Symbol |
CUSIP |
Number of
Accounts |
Outstanding
Shares |
Net Assets |
| A |
May 28, 1982 |
PHSTX |
746778109 |
137,440 |
27,643,844 |
1,607,509,579 |
| B |
March 1, 1993 |
PHSBX |
746778208 |
48,951 |
5,536,145 |
284,519,033 |
| C |
July 26, 1999 |
PCHSX |
746778307 |
3,751 |
589,329 |
32,246,960 |
| M |
July 3, 1995 |
PHLMX |
746778406 |
2,436 |
396,877 |
21,684,145 |
| Totals |
|
|
|
192,578 |
34,166,195 |
1,945,959,716 |
top of page ^
Investment Management
top of page ^
Prospectus
You agree to receive this prospectus electronically and to read and agree to its terms before investing or sending money. It contains detailed information about the fund's investment policies, risks, charges and expenses. You can read and print the prospectus while you are online, using a supported browser and Adobe Acrobat Reader™ software. If you would like a preprinted copy of the prospectus, please contact your Edward Jones financial advisor.
This prospectus is not an offer to sell, or a solicitation of an offer to buy shares in the fund nor shall any such shares be offered or sold to any person in any jurisdiction in which such offer, solicitation, purchase, or sale would be unlawful under the securities laws of such jurisdiction.
top of page ^
Copyright 2007, Putnam Retail Management
|
